Grand View Research found that North America accounts for the largest revenue share, with more than 75% of the GLP-1 agonists market. While other alternative obesity interventions exist, including ...

There is no exact known number of GLP-1 patients who say their say their sense of taste has changed since starting the ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Claudia Oshry got real about her postpartum body. Oshry, 31, took to Instagram on Monday, December 15, to share that she’s ...

A notable finding is that audiences are split on whether they see more pharma ads in 2025 compared to 2024. Nearly half of ...

Novo Nordisk finds itself navigating significant operational and market headwinds. The company is intensely focused on maintaining its leadership in the obes ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

Eli Lilly's new drug outperforms its predecessor in weight loss, the weight-loss drug market is expected to surge, Johnson & ...

No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading ...

Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma ...